AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Completed · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

The purpose of this study is to assess the effect and safety of AZD6244(ARRY-142886)versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer. Following baseline assessments, a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or pemetrexed. Treatment will be continued for as long as patients receive clinical benefit.

Key facts

Study ID

NCT00372788

Run by

AstraZeneca

People needed

88

Starts

2006-08-01

Expected to finish

2008-12-01

Last updated by the study team

2014-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with non-small cell lung cancer
• Previously received one or two chemotherapeutic treatments

You may not qualify if…

• Previous therapy with MEK inhibitor or pemetrexed
• Any recent surgery, unhealed surgical incision or severe condition such as uncontrolled cardiac disease or chronic gastrointestinal diseases

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — Ann Arbor, Michigan, United States
• Research Site — New York, New York, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Plovdiv, Bulgaria
• Research Site — Sofia, Bulgaria
• Research Site — Varna, Bulgaria
• Research Site — Cluj-Napoca, Romania

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.